FDA Announces Recall of Over 20 Million Eggs After Salmonella Outbreak in 7 States
On June 6, 2025, the U.S. Food and Drug Administration (FDA) announced that August Egg Company of Hilmar, California, is recalling over 1,700,000 dozen brown cage-free and brown certified organic eggs, totaling over 20 million eggs. The recall was initiated in response to an ongoing investigation by the FDA and the Centers for Disease Control and Prevention (CDC) into a multistate outbreak of Salmonella that has sickened 79 people and resulted in 21 hospitalizations so far.
While the eggs were produced by August Egg Company, they were sold under multiple brand names at restaurants and retailers. This recall includes eggs sold in 6-, 12-, and 18-count packs as well as larger restaurant boxes under the following brand names: Clover, First Street, Nulaid, O Organics, Marketside, Raley's, Simple Truth, Sun Harvest, and Sunnyside.
The recalled eggs were distributed from Feb. 3, 2025, through May 6, 2025, to Walmart locations in nine states: Arizona, California, Illinois, Indiana, Nebraska, Nevada, New Mexico, Washington, and Wyoming, These eggs have "sell by" dates ranging from March 4, 2025, to June 4, 2025.
The eggs were also distributed from Feb. 3, 2025, through May 15, 2025, to several retailers in California and Nevada, including Save Mart, FoodMaxx, Lucky, Smart & Final, Safeway, Raley's, Food 4 Less, and Ralphs. These eggs have "sell by" dates ranging from March 4, 2025, to June 19, 2025.
At this time, the Salmonella outbreak investigation is ongoing, with illnesses reported in seven states: Arizona, California, Kentucky, Nebraska, Nevada, New Jersey, and Washington. The FDA is working to determine if the eggs were distributed to any other retailers in additional states. The recall may be updated as more information becomes available.
You can identify the recalled eggs by checking the side of the carton. The recalled eggs feature a printed Julian Date on the side between '32' and '126' followed by a plant code number 'P-6562' or 'CA-5330' on the egg carton or package. The recalled eggs sold to consumers are packed in fiber or plastic cartons, with the above codes printed on one side of the carton.
Here is a full list of the recalled eggs, along with their identifying information:
Item Name
Plant Number
Carton UPC
Clover Organic Large Brown 12 eggs
P-6562 or CA-5330
070852010427
First Street Cage Free Large Brown Loose (1 case = 150 eggs)
P-6562 or CA-5330
041512039638
Nulaid Medium Brown Cage Free 12 eggs
P-6562 or CA-5330
071230021042
Nulaid Jumbo Brown Cage Free 12 eggs
P-6562 or CA-5330
071230021011
O Organics Cage Free Large Brown 6 eggs
P-6562 or CA-5330
079893401522
O Organics Large Brown 12 eggs
P-6562 or CA-5330
079893401508
O Organics Large Brown 18 eggs
P-6562 or CA-5330
079893401546
Marketside Organic Large Cage Free Brown 12 eggs
P-6562 or CA-5330
681131122771
Marketside Organic Large Cage Free Brown 18 eggs
P-6562 or CA-5330
681131122801
Marketside Large Cage Free Brown 12 eggs
P-6562 or CA-5330
681131122764
Marketside Large Cage Free Brown 18 eggs
P-6562 or CA-5330
681131122795
Raley's Large Cage Free Brown 12 eggs
P-6562 or CA-5330
046567033310
Raley's Large Cage Free Brown 18 eggs
P-6562 or CA-5330
046567040325
Raley's Organic Large Cage Free Brown 12 eggs
P-6562 or CA-5330
046567028798
Raley's Organic Large Cage Free Brown 18 eggs
P-6562 or CA-5330
046567040295
Simple Truth Medium Brown Cage Free 18 eggs
P-6562 or CA-5330
011110099327
Simple Truth Large Brown Cage Free 18 eggs
P-6562 or CA-5330
011110873743
Sun Harvest Organic Cage Free Large Brown 12 eggs
P-6562 or CA-5330
041512131950
Sun Harvest Organic Cage Free Large Brown 18 eggs
P-6562 or CA-5330
041512145162
Sunnyside Large Brown Cage Free 12 eggs
P-6562 or CA-5330
717544211747
Sunnyside Large Brown Cage Free 18 eggs
P-6562 or CA-5330
717544211754
Sunnyside Organic Cage Free Large Brown 12 eggs
P-6562 or CA-5330
717544201441
Sunnyside Organic Cage Free Large Brown 18 eggs
P-6562 or CA-5330
717544211761
Loose Small Brown Cage Free (1 box = 6 flats) (1 flat = 30 eggs)
P-6562 or CA-5330
NA
Loose Medium Brown Cage Free (1 box = 6 flats) (1 flat = 30 eggs)
P-6562 or CA-5330
NA
Loose Medium Brown Organic (1 box = 6 flats) (1 flat = 30 eggs)
P-6562 or CA-5330
NA
Loose Large Brown Organic (1 box = 6 flats) (1 flat = 30 eggs)
P-6562 or CA-5330
NA
Loose Jumbo Brown Cage Free (1 box = 5 flats) (1 flat = 20 eggs)
P-6562 or CA-5330
NA
Loose Jumbo Brown Organic (1 box = 5 flats) (1 flat = 20 eggs)
P-6562 or CA-5330
NA
You can also view photos of the labels on the FDA website.
The recalled eggs are no longer in stores, but the FDA is concerned they may still be in consumers' homes. Per FDA guidance, check your refrigerators for the recalled brown cage-free and brown certified organic eggs. If you have the recalled eggs, throw them away or return them to the original place of purchase for a full refund.
If you stored the eggs without their original packaging and can't tell if they are part of this outbreak, the FDA urges you to discard them out of an abundance of caution. Additionally, be sure to carefully clean and sanitize any surfaces that may have come in contact with the contaminated eggs.
Further questions about this recall may be directed to August Egg Company at 1-800-710-2554, between 9 a.m. and 5 p.m. PT.
If you believe you have already consumed the recalled eggs, you should monitor yourself for symptoms of a Salmonella infection. The most common symptoms include diarrhea, stomach cramps, dehydration, vomiting, and fever higher than 102°F—and, typically, symptoms begin between six hours and six days after eating the contaminated food. If you're experiencing any of those symptoms, contact your healthcare provider.
While most individuals feel better after four to seven days, Salmonella can cause serious infections in children, older individuals, and those with weakened immune systems. To learn more about Salmonella, visit the CDC website.
Read the original article on ALLRECIPES
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Newly approved therapy could offer another option for protecting infants from RSV, a common infection that can be deadly
The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that's the No. 1 cause of hospitalization in infants. The US Food and Drug Administration has approved a new monoclonal antibody to help prevent infection, according to an announcement late Monday from drugmaker Merck. The therapy, Enflonsia, is designed to be given in a single 105-milligram shot to protect newborns and infants from mild, moderate or severe RSV through all five months of their first virus season, which typically starts in the fall and goes through the next spring. Study materials that Merck submitted to the FDA for its approval showed that the antibody had a similar safety profile as a placebo. The most common adverse reactions from Enflonsia were mild and included injection-site swelling and a rash in a small number of infants. In a mid- to late-stage trial, Enflonsia reduced RSV-associated hospitalizations in infants more than 84% compared with a placebo. RSV can sometimes turn into serious lower respiratory infections like pneumonia, but the shot also reduced lower respiratory infections that needed medical attention by more than 60% compared with a placebo. 'Enflonsia provides an important new preventive option to help protect healthy and at-risk infants born during or entering their first RSV season,' Dr. Dean Y. Li, president of Merck Research Laboratories, said in a news release. 'We are committed to ensuring availability of Enflonsia in the US before the start of the upcoming RSV season to help reduce the significant burden of this widespread seasonal infection on families and health care systems.' Merck says it hopes Enflonsia will be available before the start of the 2025-26 respiratory virus season. First, it needs to be recommended by the US Centers for Disease Control and Prevention, and that means going in front of the agency's Advisory Committee on Immunization Practices. It's on the agenda for the panel's meeting this month, but US Health and Human Services Secretary Robert F. Kennedy removed all the members of that committee Monday. He says he will appoint new ones, but it's unclear how long that process will take. Doctors say another tool to prevent RSV cannot come soon enough. RSV is ubiquitous, one of the most common causes of childhood illness. Most kids will catch this highly contagious respiratory virus at some point before they turn 2, according to the CDC. For many healthy adults and older kids, RSV causes a mild illness like a cold. Typically, symptoms can be managed at home, and they often go away on their own. But for infants and the elderly, it can be a different story. Very young children's immune systems are just starting to learn how to fight infections, and infants have tiny airways. RSV inflames those airways, making it difficult to breathe, and can turn into a serious lower respiratory illness like bronchiolitis or pneumonia. Some of these RSV infections can be deadly. Two to three percent of infants under 6 months are hospitalized with RSV in the US every year, according to the CDC. Among children younger than 5, about 58,000 to 80,000 are hospitalized due to RSV. There's no specific medicine to treat RSV. Doctors can give an infant supportive care and oxygen, and then they essentially wait until their oxygen levels get back to normal, said Dr. Amy Edwards, director of pediatric infection control at UH Rainbow Babies and Children's Hospital in Cleveland. 'I hate RSV,' said Edwards, who was not connected with the Merck trial. 'Just to watch them struggle to breathe, and then they get scared, and then they cry, which of course makes the breathing worse, and their little lips turn blue. It's just so hard to watch.' Enflonsia joins a handful of other tools recently made available to protect babies from, although the FDA put RSV vaccine trials involving infants and young children ages 2 to 5 on hold last year after some developed severe illness. To prevent RSV in infants, the CDC currently recommends an RSV antibody made by Sanofi and AstraZeneca, called Beyfortus, which was approved in 2023. It was in short supply during that year's RSV season, although Edwards said supply started to catch up with demand in her health care system last season, and the company pledged to produce more. The other option to protect an infant is a vaccine that a person can get during pregnancy. Together, Beyfortus and the vaccine have made a difference. A CDC study published in March found that RSV-associated hospitalization rates among infants up to 7 months during 2024-25 season were lower than in seasons when those therapies weren't available. Edwards just hopes people will get protection for their infants. 'Every RSV season fills us to the gills,' she said. 'This should theoretically empty us out, if we have good uptake.'
Boston Globe
an hour ago
- Boston Globe
FDA looks to AI to enhance efficiency
Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up The agency plays a central role in pursuing the agenda of the US health secretary, Robert F. Kennedy Jr., and it has already begun to press food makers to eliminate artificial food dyes. The new road map also underscores the Trump administration's efforts to smooth the way for major industries with an array of efforts aimed at getting products to pharmacies and store shelves quickly. Advertisement Some aspects of the proposals outlined in JAMA were met with skepticism, particularly the idea that AI is up to the task of shearing months or years from the painstaking work of examining applications that companies submit when seeking approval for a drug or high-risk medical device. Advertisement 'I don't want to be dismissive of speeding reviews at the FDA,' said Stephen Holland, a lawyer who formerly advised the House Committee on Energy and Commerce on health care. 'I think that there is great potential here, but I'm not seeing the beef yet.' A major AI rollout closely follows the release of a report by Kennedy's MAHA Commission, which uses an acronym for Make America Healthy Again, that was found to be rife with references to scientific research apparently fabricated by an AI program. For some cases, the FDA officials proposed speeding major drug approvals by requiring only one major study in patients rather than two, a practice the agency has used in recent years. The pandemic provided a precedent, they said, for accelerating the process. 'We believe this is clear demonstration that rapid or instant reviews are possible,' Makary and Prasad wrote. But Holland pointed out that during the pandemic, many staff members were transferred from routine duties, including overseas inspections of food or drug facilities, and reassigned to hasten critical COVID product reviews. The agency was also better staffed. In recent months, the FDA shed about 1,940 employees, reducing the workforce to 8,000 from roughly 10,000. Last week, the agency introduced Elsa, an AI large-language model similar to ChatGPT. The FDA said it could be used to prioritize which food or drug facilities to inspect, to describe side effects in drug safety summaries and to perform other basic product-review tasks. The FDA officials wrote that AI held the promise to 'radically increase efficiency' in examining as many as 500,000 pages submitted for approval decisions. Advertisement Current and former health officials said the AI tool was helpful but far from transformative. For one, the model limits the number of characters that can be reviewed, meaning it is unable to do some rote data analysis tasks. Its results must be checked carefully, so far saving little time. Staff members said the model was hallucinating, or producing false information. Employees can ask the Elsa model to summarize text or act as an expert in a particular field of medicine. Makary said the AI models were not being trained by data submitted by the drug or medical device industry. When it comes to food oversight, Makary and Prasad said there would be a renewed focus on 'our increasingly chemically manipulated diet,' a goal embraced by Republicans and Democrats. 'For all additives,' the article said, 'the benefit-to-harm balance must be reevaluated.' Although the Trump administration is seeking steep cuts in the FDA's budget for the next fiscal year, the food division is expected to receive additional funds. Others noted the fine line agency officials were walking, given Kennedy's complaints that the FDA is too close to the drug industry and the Trump administration's business-friendly approach. Makary and Prasad wrote that the FDA must be 'partners with industry' while avoiding 'a cozy relationship that has characterized the agency in the past.' Dr. Reshma Ramachandran, a director of the Yale Collaboration for Regulatory Rigor, Integrity and Transparency, pointed out that Makary and Prasad were going on a six-city, closed-door listening tour to meet with chief executives of the drug industry. 'How is this guarding the agency 'against a cozy relationship' with industry?' she asked. The FDA priorities 'read as though they're straight out of PhRMA's playbook,' she said, referring to the trade group. Advertisement This article originally appeared in
Yahoo
an hour ago
- Yahoo
Growth Hormone Deficiency Market to Register Incremental Growth at a CAGR of 5.7% During the Forecast Period (2025-2034)
The growth hormone deficiency market is expected to see expansion across the 7MM driven by the introduction of innovative therapies, including LUM-201 and SCO-240, among others. Furthermore, the rising prevalence of growth hormone deficiency, driven by improved diagnostics, higher survival rates of premature infants, increased pituitary disorders, and environmental factors like endocrine-disrupting chemicals, is expected to drive market growth for growth hormone replacement therapies. LAS VEGAS, June 10, 2025 /PRNewswire/ -- Growth hormone deficiency (GHD) is a rare condition resulting from inadequate secretion of growth hormone by the anterior pituitary gland. It can originate from birth, develop later in life, or have no known cause, underscoring the intricate mix of genetic, environmental, and diagnostic influences. Idiopathic cases are particularly difficult to address due to the absence of identifiable causes, revealing gaps in current understanding of the condition's underlying biology. According to DelveInsight, there were approximately 207,000 prevalent GHD cases across the 7MM in 2024, with around 165,000 diagnosed. This number is projected to increase by 2034. The United States accounted for the largest share of diagnosed prevalent cases in 2024, with roughly 70,000 cases—a figure expected to grow over the 2025–2034 forecast period. Current treatment options for GHD include approved therapies such as SOGROYA, SKYTROFA, and NGENLA. Standard treatment typically involves daily subcutaneous injections, which can be particularly burdensome for children, especially those with a fear of needles. Learn more about growth hormone deficiency treatment guidelines @ Growth Hormone Deficiency Treatment Market SOGROYA (somapacitan-beco) is a long-acting human growth hormone (hGH) analog that replicates the function of natural growth hormone. It's approved for children aged 2.5 years and older with growth failure due to insufficient endogenous GH and is also indicated as replacement therapy for adults with GHD. SOGROYA works by binding to a dimeric GH receptor on target cells, activating downstream signaling pathways, and producing effects largely mediated by liver-derived IGF-1. Key regulatory approvals include: FDA approval for adult GHD in August 2020 and for pediatric GHD in April 2023; EMA approval in March 2021; and PMDA approval in Japan for adult GHD in January 2021 and for pediatric growth issues in June 2023. SKYTROFA/TRANSCON hGH (lonapegsomatropin-tcgd) is a pegylated, long-acting hGH formulated for once-weekly subcutaneous administration. It's approved in both the US and EU for pediatric patients (aged ≥1 year, ≥11.5 kg) with growth failure due to inadequate GH levels. It binds to GH receptors, initiating intracellular signaling and delivering both direct (e.g., tissue and metabolic regulation) and indirect (via IGF-1) effects, including chondrocyte development, increased hepatic glucose production, protein synthesis, and fat breakdown. Regulatory milestones include FDA approval in August 2021 for pediatric GHD, EU approval in January 2022 for patients aged 3–18, and an sBLA accepted by the FDA in December 2024 for adult GHD, with a PDUFA decision expected in July 2025. NGENLA (somatrogon-ghla) is another long-acting hGH analog developed to address inadequate natural GH production. Approved for children aged 3 and above with growth failure, NGENLA distinguishes itself from daily-injection therapies like GENOTROPIN by offering once-weekly dosing through an adjustable delivery device. It binds GH receptors and activates STAT5b signaling, leading to elevated IGF-1 and promoting linear growth and metabolic effects. NGENLA is approved in the US, EU, and Japan for pediatric GHD and is undergoing global Phase III trials for adult GHD. Regulatory highlights include US FDA approval in June 2023, European Commission approval in February 2022, and PMDA approval in January 2022. In July 2024, OPKO Health entered into a USD 250 million non-dilutive note agreement with HealthCare Royalty, backed by profit-sharing proceeds from its 2014 global partnership with Pfizer. Find out more on FDA-approved growth hormone deficiency treatment @ Growth Hormone Deficiency Drugs Market Existing treatments for growth hormone deficiency typically involve subcutaneous injections, available in both daily and newer weekly formats. However, the need for daily administration can be particularly difficult for children, often resulting in low adherence. To address this issue and enhance patient compliance, researchers are developing long-acting and oral alternatives. Companies like Lumos Pharma and SCOHIA PHARMA are advancing their candidates through clinical trials, contributing to innovation in the growth hormone deficiency space and opening up substantial opportunities for market growth. Discover which therapies are expected to grab major growth hormone deficiency market share @ Growth Hormone Deficiency Therapy LUM-201 (ibutamoren), an oral small molecule developed by Lumos Pharma, functions as an agonist of the growth hormone secretagogue receptor to stimulate the natural pulsatile release of growth hormone (GH). This targeted approach supports its use in conditions requiring enhanced GH production. Clinical studies have shown that LUM-201 is both safe and consistently effective in promoting GH secretion. Notably, the Phase II OraGrowtH210 and OraGrowtH212 trials in children with pediatric growth hormone deficiency (PGHD) successfully met all primary and secondary endpoints, reinforcing the drug's therapeutic value. In 2017, LUM-201 was granted orphan drug designation (ODD) in both the US and EU for treating growth hormone deficiency, which provides development incentives. Data presented at the European Society for Paediatric Endocrinology conference in November 2024 demonstrated sustained growth over 24 months, affirming the effectiveness of its pulsatile secretion mechanism. In December 2024, Double Point Ventures acquired Lumos Pharma through a tender offer, paying USD 4.25 per share along with contingent value rights. SCO-240, from SCOHIA PHARMA, is an oral small molecule that selectively blocks Somatostatin Receptor 5 (SSTR5), a receptor involved in hormonal regulation. While the exact function of SSTR5 in humans remains under investigation, SCO-240 has shown encouraging results in enhancing GH secretion. In a Phase I clinical study, the drug triggered significant GH release without disrupting other pituitary hormones, underscoring the therapeutic potential of SSTR5 antagonism for GH-related conditions. The compound exhibited a strong safety profile, was well-tolerated, and is suitable for once-daily oral use. In June 2023, findings from the study were presented at the 96th Annual Congress of the Japan Endocrine Society, highlighting its promise in treating GH deficiency, female infertility, and alopecia. In February 2024, SCO-240 was selected for AMED's Orphan Drug Prior to Designation support program, securing funding for its continued development in PGHD. Discover more about drugs for growth hormone deficiency in development @ Growth Hormone Deficiency Clinical Trials The anticipated launch of these emerging therapies for growth hormone deficiency are poised to transform the market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the growth hormone deficiency market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. DelveInsight estimates that the market size for growth hormone deficiency is expected to grow from USD 1.4 billion in the 7MM in 2024 at a significant 5.7% CAGR by 2034. This growth across the 7MM is expected to be fueled by the launch of novel therapies such as LUM-201 and SCO-240, among others. Additionally, the increasing prevalence, attributed to advancements in diagnostic capabilities, improved survival rates of premature infants, a rise in pituitary disorders, and environmental influences like endocrine-disrupting chemicals, is projected to boost the demand for growth hormone replacement therapies. DelveInsight's latest published market report, titled as Growth Hormone Deficiency Market Insight, Epidemiology, and Market Forecast – 2034, will help you to discover which market leader is going to capture the largest market share. The report provides comprehensive insights into the growth hormone deficiency country-specific treatment guidelines, patient pool analysis, and epidemiology forecast to help understand the key opportunities and assess the market's underlying potential. The growth hormone deficiency market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: Total Prevalent Cases of Growth Hormone Deficiency Total Diagnosed Prevalent Cases of Growth Hormone Deficiency Total Diagnosed Prevalent Cases of Pediatric Growth Hormone Deficiency Total Diagnosed Prevalent Cases of Adult Growth Hormone Deficiency Gender-specific Cases of Growth Hormone Deficiency Etiology-specific Cases of Growth Hormone Deficiency The report provides an edge while developing business strategies by understanding trends shaping and driving the 7MM growth hormone deficiency market. Highlights include: 10-year Forecast 7MM Analysis Epidemiology-based Market Forecasting Historical and Forecasted Market Analysis upto 2034 Emerging Drug Market Uptake Peak Sales Analysis Key Cross Competition Analysis Industry Expert's Opinion Access and Reimbursement Download this growth hormone deficiency market report to assess the epidemiology forecasts, understand the patient journeys, know KOLs' opinions about the upcoming treatment paradigms, and determine the factors contributing to the shift in the growth hormone deficiency market. Also, stay abreast of the mitigating factors to improve your market position in the growth hormone deficiency therapeutic space. Related Reports Growth Hormone Deficiency Epidemiology Forecast Growth Hormone Deficiency Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted GHD epidemiology in the 7MM, i.e., the United States, EU4 (Germany, Spain, Italy, France) and the United Kingdom, and Japan. Growth Hormone Deficiency Pipeline Growth Hormone Deficiency Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key GHD companies, including Novo Nordisk, Ascendis Pharma, among others. Adult Growth Hormone Deficiency Market Adult Growth Hormone Deficiency Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key adult growth hormone deficiency companies, including Novo Nordisk, Ascendis Pharma, among others. Pediatric Growth Hormone Deficiency Market Pediatric Growth Hormone Deficiency Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key pediatric growth hormone deficiency companies, including TJ Biopharma, Lumos Pharma, SCOHIA PHARMA, Inc., among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact Us Shruti Thakur info@ +14699457679 Logo: View original content: SOURCE DelveInsight Business Research, LLP Melden Sie sich an, um Ihr Portfolio aufzurufen.
